Related Experiment Videos
Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages
L J Marques1, L Zheng, N Poulakis
1Department of Pneumology and Allergy, Ruhrlandklinik, Medical Faculty, University of Essen, Germany.
Abstract:
Tumor necrosis factor-alpha (TNF-alpha) is an important proinflammatory cytokine. Recently, pentoxifylline (POF) has been shown to suppress the synthesis of TNF-alpha from lipopolysaccharide (LPS)-stimulated human monocytes in cell cultures and in vivo. The aim of this study was to investigate whether POF-induced suppression of TNF-alpha secretion affects peripheral blood monocytes (PBM) and alveolar macrophages (AM) equally, and whether POF is able to suppress the spontaneous TNF-alpha production from AM in pulmonary sarcoidosis in vitro. In seven patients without interstitial lung disease we studied the effect of POF on LPS-stimulated PBM and AM cultured for 24 h. In six patients with sarcoidosis we investigated the effect of POF on the enhanced spontaneous TNF-alpha production by AM in vitro. POF induced a dose-dependent suppression of the LPS-stimulated TNF-alpha production which was not different for PBM and AM, respectively. In sarcoidosis, POF inhibited the spontaneous TNF-alpha production of AM at 0.1 mM by 91% and at 1 mM by 98%. In conclusion, POF inhibits LPS-induced TNF-alpha production from PBM and AM to a similar extent and can also inhibit the exaggerated spontaneous TNF-alpha production from AM in sarcoidosis in vitro. This may be the basis for further clinical trials to evaluate POF as an immunotherapeutic agent in sarcoidosis.
Insights
Pentoxifylline (POF) effectively suppresses tumor necrosis factor-alpha (TNF-alpha) production in both peripheral blood monocytes and alveolar macrophages. This finding supports POF
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Tumor necrosis factor-alpha (TNF-alpha) is a key proinflammatory cytokine.
- Pentoxifylline (POF) has demonstrated efficacy in suppressing TNF-alpha synthesis.
- The role of POF in modulating TNF-alpha in specific cell types and disease states requires further investigation.
Purpose of the Study:
- To determine if POF suppresses TNF-alpha secretion equally in peripheral blood monocytes (PBM) and alveolar macrophages (AM).
- To assess POF's ability to inhibit spontaneous TNF-alpha production by AM in pulmonary sarcoidosis.
- To evaluate POF as a potential immunotherapeutic agent for sarcoidosis.
Main Methods:
- Investigated POF's effect on lipopolysaccharide (LPS)-stimulated PBM and AM in vitro.
- Studied POF's impact on spontaneous TNF-alpha production in AM from sarcoidosis patients.
- Utilized cell culture techniques with varying concentrations of POF.
Main Results:
- POF demonstrated dose-dependent suppression of LPS-stimulated TNF-alpha production in both PBM and AM.
- POF significantly inhibited spontaneous TNF-alpha production in AM from sarcoidosis patients (91% at 0.1 mM, 98% at 1 mM).
- The suppression of TNF-alpha was comparable between PBM and AM.
Conclusions:
- POF effectively inhibits both induced and spontaneous TNF-alpha production in relevant immune cells.
- POF shows promise as an immunotherapeutic agent for conditions like sarcoidosis characterized by exaggerated TNF-alpha production.
- Further clinical trials are warranted to explore POF's therapeutic potential in sarcoidosis.